UnknownPhase 1NCT03384121
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH
Studying Autosomal recessive infantile hypercalcemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Hospital for Sick Children
- Principal Investigator
- Etienne Sochett, MDThe Hospital for Sick Children
- Intervention
- Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension(drug)
- Enrollment
- 5 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2018 – 2021
Study locations (1)
- The Hospital for Sick Children, Toronto, Ontario, Canada
Collaborators
Children's Hospital of Philadelphia · Canadian Institutes of Health Research (CIHR) · Cures Within Reach
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03384121 on ClinicalTrials.govOther trials for Autosomal recessive infantile hypercalcemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT04987073Vitamin D Analog in Vitamin D 24-hydroxylase DeficiencyUniversity Hospital, Caen
- RECRUITINGPHASE2NCT03301038Rifampin in CYP24A1-related Hypercalcemia and HypercalciuriaChildren's Hospital of Philadelphia
See all trials for Autosomal recessive infantile hypercalcemia →